Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2025
0mins
Should l Buy HUMA?
Source: Benzinga
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUMA
Wall Street analysts forecast HUMA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.794
Low
3.00
Averages
5.88
High
11.00
Current: 0.794
Low
3.00
Averages
5.88
High
11.00
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humacyte Submits Marketing Authorization Application in Israel
- Market Authorization Application: On March 17, 2026, Humacyte submitted a Marketing Authorization Application to the Israel Ministry of Health for its acellular tissue-engineered vessel, Symvess, aimed at arterial trauma repair, which could significantly enhance its competitive position in the Israeli market if approved.
- Hospital Rollout Strategy: The company is pursuing a pathway to introduce Symvess on a hospital-by-hospital basis in Israel, a strategy that will help establish market presence and build trust among hospitals ahead of potential approval.
- Clinical Trial Data: In the V005 trial, Symvess demonstrated a 92.9% infection-free rate and an 87.3% limb salvage rate among 54 patients, showcasing its effectiveness in scenarios where standard vein grafts are not feasible, thereby reinforcing its clinical application potential.
- FDA Approval Context: Symvess is currently approved by the FDA for extremity vascular trauma, and while other uses remain investigational, its performance in clinical data lays a solid foundation for future market expansion.
See More
Health Care Stocks Decline on Thursday Afternoon
- Healthcare Index Decline: The NYSE Health Care Index fell by 0.4% on Thursday afternoon, indicating a decline in overall market confidence in the healthcare sector, which may influence investors' decisions regarding stock holdings.
- Market Sentiment Weakens: The drop in healthcare stocks may be linked to broader economic uncertainties, as investor concerns about future economic growth intensify, leading to capital outflows from the healthcare sector and impacting its short-term performance.
- Investor Reactions: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors that are performing better to mitigate risk and seek higher returns.
- Uncertain Industry Outlook: The future performance of the healthcare sector may be influenced by policy changes and market dynamics, prompting investors to closely monitor relevant policy developments to adjust their investment strategies accordingly.
See More
Humacyte Plans to Sell 25 Million Shares to Raise $20 Million
- Fundraising Initiative: Humacyte is set to sell 25 million shares at $0.80 each, aiming to raise $20 million, which represents a 25% discount from the previous day's closing price, likely leading to a significant drop in stock value.
- Commercialization Support: The proceeds will be allocated to support the commercialization of Symvess for vascular trauma and to advance a Biologics License Application supplement for hemodialysis, indicating the company's commitment to product development.
- Saudi Arabia Commitment: Humacyte has secured a $1.5 million minimum purchase commitment from Saudi Arabia and agreed not to pursue other commercialization negotiations until July 2026, aiming to foster partnerships with local medical institutions.
- Clinical Evaluation Program: The company plans to implement a clinical evaluation and outreach program to enhance healthcare providers' awareness of Symvess technology, preparing for a potential commercial launch in Saudi Arabia.
See More
Humacyte Secures $1.475 Million Purchase Commitment for Symvess
- Purchase Commitment: Humacyte announced a minimum purchase commitment of $1.475 million to support its clinical evaluation and outreach program for the Symvess tissue-engineered vessel in Saudi Arabia, indicating growing market recognition and demand for its product.
- Collaboration Plans: The program will run alongside ongoing negotiations with a Saudi-based entity to establish a joint venture and licensing agreement for the commercialization of Symvess, further expanding the company's market share and influence.
- Professional Training: Humacyte will provide training to medical professionals to ensure effective use and promotion of its product, while agreeing not to pursue other commercialization negotiations in Saudi Arabia until July 2, 2026, to maintain a strong relationship with its local partner.
- Regulatory Status: Although Symvess has received regulatory approval in the U.S., it remains investigational for uses beyond that approval, and the finalization of the joint venture and licensing deal will depend on further negotiations and definitive agreements, reflecting the company's cautious approach to market expansion.
See More
Eligibility Verification for Huma Open Season 3 Airdrop
- Eligibility Check Announcement: Huma Finance has announced that the eligibility check for the third-quarter air drop is now open.
- Air Drop Details: The announcement indicates that participants can now verify their eligibility for the upcoming air drop event.
See More
Humacyte Secures Congressional Funding for Bioengineered Vessels
- Legislative Support: The U.S. Congress passed the FY 2026 DoD Appropriations Act, providing funding for Humacyte's human-derived bioengineered vessel, Symvess, which is expected to enhance the company's market share in treating traumatic vascular injuries.
- Integration Requirement: The bill mandates the DoD to integrate FDA-approved breakthrough vascular repair technologies, ensuring the availability of biologically active vascular conduits when autologous vein harvesting is not feasible, thereby increasing demand for Humacyte's products.
- FDA Approval: In December 2024, the FDA approved Symvess as an implantable vascular conduit for various arterial injury scenarios, marking a significant technological breakthrough for Humacyte and strengthening its competitive position in the medical market.
- CEO Remarks: Humacyte's CEO Laura Niklason stated that this historic federal investment will ensure soldiers have access to cutting-edge treatments, further enhancing the company's strategic position in the defense healthcare sector.
See More
Humacyte Submits Marketing Authorization Application in Israel
- Market Authorization Application: On March 17, 2026, Humacyte submitted a Marketing Authorization Application to the Israel Ministry of Health for its acellular tissue-engineered vessel, Symvess, aimed at arterial trauma repair, which could significantly enhance its competitive position in the Israeli market if approved.
- Hospital Rollout Strategy: The company is pursuing a pathway to introduce Symvess on a hospital-by-hospital basis in Israel, a strategy that will help establish market presence and build trust among hospitals ahead of potential approval.
- Clinical Trial Data: In the V005 trial, Symvess demonstrated a 92.9% infection-free rate and an 87.3% limb salvage rate among 54 patients, showcasing its effectiveness in scenarios where standard vein grafts are not feasible, thereby reinforcing its clinical application potential.
- FDA Approval Context: Symvess is currently approved by the FDA for extremity vascular trauma, and while other uses remain investigational, its performance in clinical data lays a solid foundation for future market expansion.
See More
Health Care Stocks Decline on Thursday Afternoon
- Healthcare Index Decline: The NYSE Health Care Index fell by 0.4% on Thursday afternoon, indicating a decline in overall market confidence in the healthcare sector, which may influence investors' decisions regarding stock holdings.
- Market Sentiment Weakens: The drop in healthcare stocks may be linked to broader economic uncertainties, as investor concerns about future economic growth intensify, leading to capital outflows from the healthcare sector and impacting its short-term performance.
- Investor Reactions: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors that are performing better to mitigate risk and seek higher returns.
- Uncertain Industry Outlook: The future performance of the healthcare sector may be influenced by policy changes and market dynamics, prompting investors to closely monitor relevant policy developments to adjust their investment strategies accordingly.
See More
Humacyte Plans to Sell 25 Million Shares to Raise $20 Million
- Fundraising Initiative: Humacyte is set to sell 25 million shares at $0.80 each, aiming to raise $20 million, which represents a 25% discount from the previous day's closing price, likely leading to a significant drop in stock value.
- Commercialization Support: The proceeds will be allocated to support the commercialization of Symvess for vascular trauma and to advance a Biologics License Application supplement for hemodialysis, indicating the company's commitment to product development.
- Saudi Arabia Commitment: Humacyte has secured a $1.5 million minimum purchase commitment from Saudi Arabia and agreed not to pursue other commercialization negotiations until July 2026, aiming to foster partnerships with local medical institutions.
- Clinical Evaluation Program: The company plans to implement a clinical evaluation and outreach program to enhance healthcare providers' awareness of Symvess technology, preparing for a potential commercial launch in Saudi Arabia.
See More
Humacyte Secures $1.475 Million Purchase Commitment for Symvess
- Purchase Commitment: Humacyte announced a minimum purchase commitment of $1.475 million to support its clinical evaluation and outreach program for the Symvess tissue-engineered vessel in Saudi Arabia, indicating growing market recognition and demand for its product.
- Collaboration Plans: The program will run alongside ongoing negotiations with a Saudi-based entity to establish a joint venture and licensing agreement for the commercialization of Symvess, further expanding the company's market share and influence.
- Professional Training: Humacyte will provide training to medical professionals to ensure effective use and promotion of its product, while agreeing not to pursue other commercialization negotiations in Saudi Arabia until July 2, 2026, to maintain a strong relationship with its local partner.
- Regulatory Status: Although Symvess has received regulatory approval in the U.S., it remains investigational for uses beyond that approval, and the finalization of the joint venture and licensing deal will depend on further negotiations and definitive agreements, reflecting the company's cautious approach to market expansion.
See More
Eligibility Verification for Huma Open Season 3 Airdrop
- Eligibility Check Announcement: Huma Finance has announced that the eligibility check for the third-quarter air drop is now open.
- Air Drop Details: The announcement indicates that participants can now verify their eligibility for the upcoming air drop event.
See More
Humacyte Secures Congressional Funding for Bioengineered Vessels
- Legislative Support: The U.S. Congress passed the FY 2026 DoD Appropriations Act, providing funding for Humacyte's human-derived bioengineered vessel, Symvess, which is expected to enhance the company's market share in treating traumatic vascular injuries.
- Integration Requirement: The bill mandates the DoD to integrate FDA-approved breakthrough vascular repair technologies, ensuring the availability of biologically active vascular conduits when autologous vein harvesting is not feasible, thereby increasing demand for Humacyte's products.
- FDA Approval: In December 2024, the FDA approved Symvess as an implantable vascular conduit for various arterial injury scenarios, marking a significant technological breakthrough for Humacyte and strengthening its competitive position in the medical market.
- CEO Remarks: Humacyte's CEO Laura Niklason stated that this historic federal investment will ensure soldiers have access to cutting-edge treatments, further enhancing the company's strategic position in the defense healthcare sector.
See More
